Literature DB >> 30980600

Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors.

Jefferson M Jones1, Brian M Gurbaxani2, Alice Asher3, Stephanie Sansom4, Pallavi Annambhotla1, Anne C Moorman3, Saleem Kamili3, John T Brooks4, Sridhar V Basavaraju1.   

Abstract

To reduce the risk of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) transmission through organ transplantation, donors are universally screened for these infections by nucleic acid tests (NAT). Deceased organ donors are classified as "increased risk" if they engaged in specific behaviors during the 12 months before death. We developed a model to estimate the risk of undetected infection for HIV, HBV, and HCV among NAT-negative donors specific to the type and timing of donors' potential risk behavior to guide revisions to the 12-month timeline. Model parameters were estimated, including risk of disease acquisition for increased risk groups, number of virions that multiply to establish infection, virus doubling time, and limit of detection by NAT. Monte Carlo simulation was performed. The risk of undetected infection was <1/1 000 000 for HIV after 14 days, for HBV after 35 days, and for HCV after 7 days from the time of most recent potential exposure to the day of a negative NAT. The period during which reported donor risk behaviors result in an "increased risk" designation can be safely shortened. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  donors and donation: deceased; donors and donation: donor-derived infections; ethics and public policy; infection and infectious agents - viral; infectious disease; mathematical model; organ procurement and allocation; organ transplantation in general

Mesh:

Substances:

Year:  2019        PMID: 30980600      PMCID: PMC6946117          DOI: 10.1111/ajt.15393

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  39 in total

1.  High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors.

Authors:  P Gupta; J Mellors; L Kingsley; S Riddler; M K Singh; S Schreiber; M Cronin; C R Rinaldo
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.

Authors:  Jos J A M Weusten; Harry A J van Drimmelen; P Nico Lelie
Journal:  Transfusion       Date:  2002-05       Impact factor: 3.157

3.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.

Authors:  M A Nowak; A L Lloyd; G M Vasquez; T A Wiltrout; L M Wahl; N Bischofberger; J Williams; A Kinter; A S Fauci; V M Hirsch; J D Lifson
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation.

Authors:  Debbie L Seem; Ingi Lee; Craig A Umscheid; Matthew J Kuehnert
Journal:  Public Health Rep       Date:  2013-07       Impact factor: 2.792

Review 5.  Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion.

Authors:  Steven H Kleinman; Nico Lelie; Michael P Busch
Journal:  Transfusion       Date:  2009-07-21       Impact factor: 3.157

6.  Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms.

Authors:  Jos Weusten; Marion Vermeulen; Harry van Drimmelen; Nico Lelie
Journal:  Transfusion       Date:  2010-08-12       Impact factor: 3.157

7.  Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007.

Authors:  P R Spradling; J T Richardson; K Buchacz; A C Moorman; J T Brooks
Journal:  J Viral Hepat       Date:  2010-12       Impact factor: 3.728

Review 8.  Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

9.  HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015.

Authors:  Philip J Peters; Pamela Pontones; Karen W Hoover; Monita R Patel; Romeo R Galang; Jessica Shields; Sara J Blosser; Michael W Spiller; Brittany Combs; William M Switzer; Caitlin Conrad; Jessica Gentry; Yury Khudyakov; Dorothy Waterhouse; S Michele Owen; Erika Chapman; Jeremy C Roseberry; Veronica McCants; Paul J Weidle; Dita Broz; Taraz Samandari; Jonathan Mermin; Jennifer Walthall; John T Brooks; Joan M Duwve
Journal:  N Engl J Med       Date:  2016-07-21       Impact factor: 91.245

10.  Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections.

Authors:  Amy Lansky; Teresa Finlayson; Christopher Johnson; Deborah Holtzman; Cyprian Wejnert; Andrew Mitsch; Deborah Gust; Robert Chen; Yuko Mizuno; Nicole Crepaz
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

View more
  2 in total

1.  Successful Implementation of an Increased Viral Risk Donor Waiting List for Preconsented Kidney Transplant Candidates in Victoria, Australia.

Authors:  Darren Lee; Indra Gramnea; Nina Seng; Meaghan Bruns; Fiona Hudson; Rohit D'Costa; Leanne McEvoy; Joe Sasadeusz; Michael J O'Leary; Gopal Basu; Joshua Y Kausman; Rosemary Masterson; Kathy Paizis; John Kanellis; Peter D Hughes; David J Goodman; John B Whitlam
Journal:  Transplant Direct       Date:  2021-09-07

2.  Consent to organ offers from public health service "Increased Risk" donors decreases time to transplant and waitlist mortality.

Authors:  Yvonne M Kelly; Arya Zarinsefat; Mehdi Tavakol; Amy M Shui; Chiung-Yu Huang; John P Roberts
Journal:  BMC Med Ethics       Date:  2022-03-05       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.